Voyager Therapeutics (NASDAQ:VYGR) Stock Passes Below 50-Day Moving Average – Should You Sell?

Posted by Geri Gentry on Jul 24th, 2026

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.57 and traded as low as $3.06. Voyager Therapeutics shares last traded at $3.10, with a volume of 417,266 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on VYGR shares. HC Wainwright reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. Finally, Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Get Our Latest Stock Report on Voyager Therapeutics

Voyager Therapeutics Trading Up 0.3%

The stock has a market cap of $187.31 million, a P/E ratio of -1.57 and a beta of 1.27. The firm’s fifty day moving average is $3.54 and its 200 day moving average is $3.80.

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative return on equity of 55.97% and a negative net margin of 319.61%.The firm had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. Research analysts forecast that Voyager Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Wexford Capital LP acquired a new position in Voyager Therapeutics in the 3rd quarter valued at approximately $42,000. ProShare Advisors LLC acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth approximately $44,000. CIBC Asset Management Inc acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth approximately $45,000. Coldstream Capital Management Inc. bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $55,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Voyager Therapeutics by 42,410.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock valued at $62,000 after purchasing an additional 15,692 shares in the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.